{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:32Z","timestamp":1793971952749,"version":"4.8.0"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119020","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:08:50Z","timestamp":1769890130000},"page":"119020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations"],"prefix":"10.1016","volume":"196","author":[{"given":"Mahla","family":"Shokouhfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taha","family":"Nami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Khavari","family":"Khorasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Ghorbani","family":"Vanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-2016","authenticated-orcid":false,"given":"Nastaran","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119020_bib1","article-title":"Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs","volume":"79","author":"Nong","year":"2025","journal-title":"EClinicalMedicine [Internet]"},{"issue":"18","key":"10.1016\/j.biopha.2026.119020_bib2","article-title":"Neuroblastoma: when differentiation goes awry","volume":"110","author":"Zeineldin","year":"2025","journal-title":"Neuron [Internet]. 2022 Sep 21 [cited"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib3","first-page":"321","article-title":"Molecular basis and clinical features of neuroblastoma","volume":"4","author":"Takita","year":"2021","journal-title":"JMA J. [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41588-023-01332-y","article-title":"Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome","volume":"55","author":"K\u00f6rber","year":"2023","journal-title":"Nat. Genet [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib5","article-title":"Global burden, trends, and projections to 2050 of neuroblastoma and other peripheral nervous cell tumors: a systematic analysis of the global burden of disease study from 1990 to 2021","volume":"13","author":"Wu","year":"2025","journal-title":"Front Pedia [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib6","article-title":"The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies","volume":"11","author":"Mora","year":"2020","journal-title":"Front Pharm. [Internet]"},{"issue":"42","key":"10.1016\/j.biopha.2026.119020_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/EDBK_349783","article-title":"TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes","volume":"42","author":"DuBois","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib8","article-title":"International neuroblastoma risk group consortium: a model of networking for rare cancers","author":"Cohn","year":"2025","journal-title":"JNCI Journal National Cancer Institute [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib9","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/cancers13102467","article-title":"Bone Marrow Environment in Metastatic Neuroblastoma","volume":"13","author":"Brignole","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119020_bib10","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.3390\/ijms25147730","article-title":"Neuroblastoma-A Review of Combination Immunotherapy","volume":"25","author":"Pieni\u0105\u017cek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119020_bib11","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of Neuroblastoma: Facts and Hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s10555-024-10212-8","article-title":"Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives","volume":"43","author":"Rados","year":"2024","journal-title":"Cancer Metastas. Rev. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib13","article-title":"T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma","volume":"16","author":"Maggi","year":"2025","journal-title":"Front Immunol. [Internet]"},{"issue":"16","key":"10.1016\/j.biopha.2026.119020_bib14","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.19.01410","article-title":"Targets and Antibody Formats for Immunotherapy of Neuroblastoma","volume":"38","author":"Park","year":"2020","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib15","article-title":"The triad in current neuroblastoma challenges: Targeting antigens, enhancing effective cytotoxicity and accurate 3D in vitro modelling","volume":"51","author":"King","year":"2025","journal-title":"Transl. Oncol. [Internet]. 2024 Jan. 1 [cited"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib16","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat. Commun. [Internet]"},{"issue":"9","key":"10.1016\/j.biopha.2026.119020_bib17","first-page":"2130","article-title":"Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma","volume":"13","author":"Lutskovich","year":"2025","journal-title":"Biomed. [Internet]"},{"issue":"16","key":"10.1016\/j.biopha.2026.119020_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162865","article-title":"Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma","volume":"16","author":"Mao","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119020_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2024.100179","article-title":"GD2 targeting CAR T cells for neuroblastoma","author":"Anderson","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2026.119020_bib20","article-title":"ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation","volume":"40","author":"Boren\u00e4s","year":"2021","journal-title":"EMBO J. [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2026.119020_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/0008-5472.CAN-20-2808","article-title":"Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2026.119020_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib23","article-title":"Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib24","article-title":"The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies","volume":"3","author":"Louault","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib25","article-title":"Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib26","first-page":"20","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2026.119020_bib27","article-title":"Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (Beijing) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib28","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/jcm13164765","article-title":"High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy","volume":"13","author":"Persaud","year":"2024","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119020_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2767-9764.CRC-21-0134","article-title":"Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment","volume":"2","author":"Kacher","year":"2022","journal-title":"Cancer Res. Commun. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib30","article-title":"MYCN in neuroblastoma: The kings\u2019 new clothes and drugs","volume":"4","author":"M\u00fcller","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1186\/s12885-024-13044-5","article-title":"Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2026.119020_bib32","first-page":"305","article-title":"Masih KE, Wei JS, Milewski D, Khan J. Exploring and Targeting the Tumor Immune Microenvironment of Neuroblastoma","volume":"3","year":"2021","journal-title":"J. Cell Immunol. [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib33","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J. Immunother. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/ijms21041364","article-title":"Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status","volume":"21","author":"Curr\u00f2","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184421","article-title":"MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment","author":"Bartolucci","year":"2022","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112145","article-title":"Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas","author":"Song","year":"2024","journal-title":"Int Immunopharmacol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-023-02913-9","article-title":"Targeting the myeloid microenvironment in neuroblastoma","author":"Stip","year":"2023","journal-title":"J. Exp. Clin. Cancer Res [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib38","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.3390\/ijms22105076","article-title":"Gangliosides as Signaling Regulators in Cancer","volume":"22","author":"Sasaki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1249929","article-title":"Biology of GD2 ganglioside: implications for cancer immunotherapy","author":"Machy","year":"2023","journal-title":"Front Pharm. [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib40","article-title":"Cancer-associated glycosphingolipids as tumor markers and targets for cancer immunotherapy","volume":"22","author":"Groux-Degroote","year":"2021","journal-title":"Int J. Mol. Sci. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2024.1371345","article-title":"GD2-targeting therapy: a comparative analysis of approaches and promising directions","volume":"15","author":"Philippova","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2024.1371345","article-title":"GD2-targeting therapy: a comparative analysis of approaches and promising directions","volume":"15","author":"Philippova","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib43","doi-asserted-by":"crossref","unstructured":"Furman W.L. <p>Monoclonal Antibody Therapies for High Risk Neuroblastoma<\/p>. Biologics [Internet]. 2021 Jun 9 [cited 2025 Oct 25];15:205\u201319. Available from: \u3008https:\/\/www.dovepress.com\/monoclonal-antibody-therapies-for-high-risk-neuroblastoma-peer-reviewed-fulltext-article-BTT\u3009.","DOI":"10.2147\/BTT.S267278"},{"issue":"3","key":"10.1016\/j.biopha.2026.119020_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119020_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186641","article-title":"Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network","author":"Hern\u00e1df\u0151i","year":"2025","journal-title":"J. Clin. Med [Internet]"},{"issue":"8","key":"10.1016\/j.biopha.2026.119020_bib46","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119020_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1041443","article-title":"Dinutuximab beta plus conventional chemotherapy for relapsed\/refractory high-risk neuroblastoma: A single-center experience","author":"Olgun","year":"2022","journal-title":"Front Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib48","unstructured":"FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow | FDA [Internet]. [cited 2025 Oct 25]. Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194837","article-title":"Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes","author":"Mu\u00f1oz","year":"2023","journal-title":"Cancers (Basel) [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11523-022-00930-w","article-title":"Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma","volume":"18","author":"Balaguer","year":"2023","journal-title":"Target Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib51","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41416-023-02457-x","article-title":"Long-term, continuous infusion of single-agent dinutuximab beta for relapsed\/refractory neuroblastoma: an open-label, single-arm, Phase 2 study","volume":"129","author":"Lode","year":"2023","journal-title":"Br. J. Cancer Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib52","article-title":"Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava","volume":"101","author":"Achbergerov\u00e1","year":"2022","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.biopha.2026.119020_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-021-00469-9","article-title":"Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance","author":"Barone","year":"2021","journal-title":"Pediatr. Drugs [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib54","article-title":"Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients","volume":"10","author":"Blom","year":"2020","journal-title":"Front Oncol. Et. al."},{"issue":"8","key":"10.1016\/j.biopha.2026.119020_bib55","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-term follow-up of a phase III study of ch14.18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res. Et. al"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib56","article-title":"Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and\/or relapsed high-risk neuroblastoma: Management of adverse events","volume":"6","author":"Mora","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"issue":"16_","key":"10.1016\/j.biopha.2026.119020_bib57","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1200\/JCO.2024.42.16_suppl.10032","article-title":"Naxitamab-related adverse events within and across treatment cycles in patients with relapsed\/refractory (R\/R) high-risk neuroblastoma","volume":"42","author":"Mora","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-024-00468-5","article-title":"Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed\/Refractory High-Risk Neuroblastoma at the Children\u2019s Hospital of Fudan University","volume":"12","author":"Qian","year":"2025","journal-title":"Drugs Real. World Outcomes Et. al"},{"key":"10.1016\/j.biopha.2026.119020_bib59","doi-asserted-by":"crossref","DOI":"10.4062\/biomolther.2023.196","article-title":"Current Development Status of Cytokines for Cancer Immunotherapy","author":"Song","year":"2024","journal-title":"Biomol. Ther. (Seoul. ) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00873","article-title":"Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells","volume":"11","author":"McNerney","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib61","article-title":"Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression","author":"Kim","year":"2024","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: A Double-Edged Sword in Cancer Immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib63","article-title":"G-CSF, or No Cytokine Therapy with Anti-GD2 Immunotherapy for High-Risk Neuroblastoma","author":"Mora","year":"2023","journal-title":"Int J. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib64","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms24108470","article-title":"Biological Insight and Recent Advancement in the Treatment of Neuroblastoma","volume":"24","author":"Rivera","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib65","article-title":"Research progress of interleukin-15 in cancer immunotherapy","author":"Cai","year":"2023","journal-title":"Front Pharm. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2026.119020_bib67","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0717","article-title":"Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharm. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib69","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e22","article-title":"The Diverse Function of IL-6 in Biological Processes and the Advancement of Cancer","author":"Zhou","year":"2025","journal-title":"Immune Netw. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib70","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0717","article-title":"Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1076862","article-title":"The biological role and immunotherapy of gangliosides and GD3 synthase in cancers","author":"Cao","year":"2023","journal-title":"Front Cell Dev. Biol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib72","article-title":"Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: children\u2019s oncology group study ANBL0032","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res [Internet]"},{"issue":"14","key":"10.1016\/j.biopha.2026.119020_bib73","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med. Et. al."},{"issue":"8","key":"10.1016\/j.biopha.2026.119020_bib74","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ijc.34815","article-title":"G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma","volume":"154","author":"Mora","year":"2024","journal-title":"Int J. Cancer"},{"issue":"17","key":"10.1016\/j.biopha.2026.119020_bib75","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.22.01630","article-title":"Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I\/II Trial","volume":"41","author":"Flaadt","year":"2023","journal-title":"J. Clin. Oncol. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.21.01375","article-title":"Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322","volume":"40","author":"Furman","year":"2022","journal-title":"A. J. Clin. Oncol. Et. al."},{"issue":"12","key":"10.1016\/j.biopha.2026.119020_bib77","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol. Et. al."},{"key":"10.1016\/j.biopha.2026.119020_bib78","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.3390\/cancers15194722","article-title":"Neuroblastoma in the Era of Precision Medicine: A Clinical Review","volume":"15","author":"Wahba","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119020_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1353860","article-title":"Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions","volume":"12","author":"Zheng","year":"2024","journal-title":"Front Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119020_bib81","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","author":"Lin","year":"2024","journal-title":"Mol. Cancer [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib82","first-page":"1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119020_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.767466","article-title":"Differential Role of PD-1 Expressed by various immune and tumor cells in the tumor immune microenvironment: expression, function, therapeutic efficacy, and resistance to cancer immunotherapy","volume":"9","author":"Kim","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119020_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","author":"Hossen","year":"2023","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: Unraveling coinhibitory interactions","author":"Burke","year":"2024","journal-title":"Immun. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib86","first-page":"1","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119020_bib87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ymthe.2022.08.025","article-title":"Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory","volume":"31","author":"El-Hajjar","year":"2023","journal-title":"Mol. Ther. Et. al."},{"issue":"3","key":"10.1016\/j.biopha.2026.119020_bib88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41435-022-00172-w","article-title":"Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma","volume":"23","author":"Tang","year":"2022","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib89","doi-asserted-by":"crossref","first-page":"2289738","DOI":"10.1080\/2162402X.2023.2289738","article-title":"PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1\/PD-L1 blockade in neuroblastoma","volume":"13","author":"Song","year":"2024","journal-title":"Oncoimmunology. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol. Et. al."},{"key":"10.1016\/j.biopha.2026.119020_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","volume":"150","author":"Pasqualini","year":"2021","journal-title":"Eur. J. Cancer Et. al."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib92","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol. Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2026.119020_bib93","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib94","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(20)30086-3","article-title":"Nivolumab in paediatric cancer: children are not little adults","volume":"21","author":"Mora","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib95","doi-asserted-by":"crossref","first-page":"1838140","DOI":"10.1080\/2162402X.2020.1838140","article-title":"Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma","volume":"10","author":"Shirinbak","year":"2021","journal-title":"Oncoimmunology. Et. al."},{"issue":"12","key":"10.1016\/j.biopha.2026.119020_bib96","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119020_bib97","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119020_bib98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","article-title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy","volume":"42","author":"Wienke","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.biopha.2026.119020_bib99","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21873\/cdp.10274","article-title":"Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival","volume":"3","author":"Meleshko","year":"2023","journal-title":"Cancer Diagn. Progn."},{"issue":"10","key":"10.1016\/j.biopha.2026.119020_bib100","article-title":"Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2026.119020_bib101","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35062","article-title":"Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients","author":"Kyr","year":"2024","journal-title":"Int J. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.730824","article-title":"Recent Advances in Experimental Dendritic Cell Vaccines for Cancer","volume":"11","author":"Filin","year":"2021","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119020_bib104","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2026.119020_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.631713","article-title":"Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer","volume":"11","author":"B\u00f6dder","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib107","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: anticancer vaccination with dendritic cells","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119020_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120621","article-title":"Current trends in cancer immunotherapy","volume":"8","author":"Filin","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119020_bib109","article-title":"Dendritic cell vaccines: Current research progress, challenges, and opportunities","author":"Zhang","year":"2025","journal-title":"Genes Dis. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib110","article-title":"Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies","author":"Olsen","year":"2021","journal-title":"Neurooncol Adv. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib111","article-title":"Advances in dendritic cell vaccination therapy of cancer","volume":"164","author":"Najafi","year":"2023","journal-title":"Biomed. Pharmacother. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","author":"Singh","year":"2025","journal-title":"Oncol. Rev. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib113","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2023.0395","article-title":"Neoantigen cancer vaccines: a new star on the horizon","author":"Li","year":"2023","journal-title":"Cancer Biol. Med [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.biopha.2026.119020_bib115","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119020_bib116","article-title":"mRNA vaccines: current applications and future directions","author":"Li","year":"2025","journal-title":"MedComm (Beijing) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib117","article-title":"Application of lipid-based nanoparticles in cancer immunotherapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib118","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-023-03568-3","article-title":"The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma","author":"Kou","year":"2023","journal-title":"Cancer Immunol. Immunother. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib119","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S450853","article-title":"Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier","author":"Lim","year":"2024","journal-title":"Int J. Nanomed. [Internet]"},{"issue":"10","key":"10.1016\/j.biopha.2026.119020_bib120","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1084\/jem.190.10.1417","article-title":"In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas","volume":"190","author":"Bell","year":"1999","journal-title":"J. Exp. Med"},{"issue":"8","key":"10.1016\/j.biopha.2026.119020_bib121","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/eji.200940098","article-title":"Plasmacytoid dendritic cell-induced migration and activation of NK cells in vivo","volume":"40","author":"Persson","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib122","first-page":"396","article-title":"Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma","volume":"5","author":"Jenkins","year":"2021","journal-title":"J. Transl. Genet Genom."},{"key":"10.1016\/j.biopha.2026.119020_bib123","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/cells14201620","article-title":"The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond","volume":"14","author":"Smestad","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119020_bib124","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119020_bib125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.54254\/2753-8818\/24\/20231094","article-title":"The use of oncolytic virus to combat neuroblastoma","volume":"24","author":"Zhao","year":"2023","journal-title":"Theor. Nat. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib126","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2023.2245326","article-title":"Oncolytic virotherapies for pediatric tumors","author":"Gross","year":"2023","journal-title":"Expert Opin. Biol. Ther. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib127","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-1382","article-title":"Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers","author":"Kang","year":"2022","journal-title":"Clin. Cancer Res [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fimmu.2022.866892","article-title":"Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality","volume":"13","author":"de la Nava","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119020_bib129","doi-asserted-by":"crossref","first-page":"1055729","DOI":"10.3389\/fped.2022.1055729","article-title":"Progress of oncolytic virotherapy for neuroblastoma","volume":"10","author":"Chen","year":"2022","journal-title":"Front Pediatr. Et. al."},{"key":"10.1016\/j.biopha.2026.119020_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133314","article-title":"Preclinical models of neuroblastoma\u2014current status and perspectives","volume":"15","author":"Krawczyk","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119020_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2022.09.003","article-title":"Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine","author":"Engeland","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/cells14221825","article-title":"A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses","author":"Su\u0142ek","year":"2025","journal-title":"Cells [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119020_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1055729","article-title":"Progress of oncolytic virotherapy for neuroblastoma","author":"Chen","year":"2022","journal-title":"Front Pedia [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00262-024-03818-y","article-title":"Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma","volume":"73","author":"Quinn","year":"2024","journal-title":"Cancer Immunol. Immunother. Et. al"},{"key":"10.1016\/j.biopha.2026.119020_bib136","article-title":"Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy","author":"Wang","year":"2021","journal-title":"Oncol. Lett. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052417","article-title":"Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors","author":"Kreppel","year":"2021","journal-title":"Int J. Mol. Sci. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119020_bib139","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11684-020-0750-4","article-title":"Development of oncolytic virotherapy: From genetic modification to combination therapy","volume":"14","author":"Lan","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.biopha.2026.119020_bib140","article-title":"Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality","volume":"13","author":"de la Nava","year":"2022","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib141","article-title":"Advances in antitumour therapy with oncolytic herpes simplex virus combinations","volume":"15","author":"Qi","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119020_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200927","article-title":"Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma","author":"Chu","year":"2025","journal-title":"Mol. Ther. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib143","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/02841860903071369","article-title":"Oncolytic adenovirus treatment of a patient with refractory neuroblastoma","volume":"49","author":"Pesonen","year":"2010","journal-title":"Acta Oncol. (Madr. ). Et. al"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib144","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"Andi\u00f3n M. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther. Et. al"},{"issue":"3","key":"10.1016\/j.biopha.2026.119020_bib145","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol. Ther. Et. al"},{"issue":"5","key":"10.1016\/j.biopha.2026.119020_bib146","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/pbc.25269","article-title":"Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed\/refractory solid tumors: A report of the Children\u2019s Oncology Group","volume":"62","author":"Burke","year":"2015","journal-title":"Pedia Blood Cancer Et. al."},{"key":"10.1016\/j.biopha.2026.119020_bib147","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03818-y","article-title":"Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma","author":"Quinn","year":"2024","journal-title":"Cancer Immunol. Immunother. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib148","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","author":"Kennedy","year":"2025","journal-title":"J. Immunother. Cancer [Internet]. 2023 Nov. 22 [cited"},{"key":"10.1016\/j.biopha.2026.119020_bib149","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3389\/fneur.2020.00919","article-title":"CSF neurofilament light chain elevation predicts ALS severity and progression","volume":"11","author":"Sun","year":"2020","journal-title":"Front Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2026.119020_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions","author":"Alnefaie","year":"2022","journal-title":"Front Bioeng. Biotechnol. [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2026.119020_bib152","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119020_bib153","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2026.119020_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2024.100179","article-title":"GD2 targeting CAR T cells for neuroblastoma","author":"Anderson","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119020_bib156","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-025-10294-y","article-title":"B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors","volume":"44","author":"Jansen","year":"2025","journal-title":"Cancer Metastas. Rev."},{"issue":"14","key":"10.1016\/j.biopha.2026.119020_bib157","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119020_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107608","article-title":"Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy","author":"Grunewald","year":"2025","journal-title":"Pharm. Res [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib159","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2018.02380","article-title":"CAR T Cell Therapy for Neuroblastoma","volume":"9","author":"Richards","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119020_bib161","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.biopha.2026.119020_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib164","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/10781552231170757","article-title":"Early versus standard management of chimeric antigen receptor therapy toxicities and management\u2019s impact on safety and efficacy","volume":"30","author":"Gaffney","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.biopha.2026.119020_bib165","article-title":"Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors","volume":"19","author":"Neeser","year":"2023","journal-title":"ImmunoOncol. Technol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib166","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","article-title":"Programmable synthetic receptors: the next-generation of cell and gene therapies","volume":"9","author":"Teng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib167","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-022-01288-2","article-title":"C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction","volume":"15","author":"Lai","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-023-00438-7","article-title":"Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119020_bib169","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib170","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119020_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106331","article-title":"Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer","volume":"180","author":"Zhong","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib172","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","author":"Kennedy","year":"2023","journal-title":"J. Immunother. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib173","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2025.14","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib174","doi-asserted-by":"crossref","DOI":"10.1002\/pdi3.2512","article-title":"Metronomic chemotherapy in pediatric neuroblastoma","author":"Jiang","year":"2024","journal-title":"Pediatr. Discov. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib175","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","author":"Jia","year":"2022","journal-title":"Exp. Hematol. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib176","article-title":"Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy","author":"Zhang","year":"2025","journal-title":"Cells [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2026.119020_bib177","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.3390\/ijms22116145","article-title":"Cancer-associated glycosphingolipids as tumor markers and targets for cancer immunotherapy","volume":"22","author":"Groux-Degroote","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2240678","article-title":"The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1","volume":"12","author":"Pilgrim","year":"2023","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.biopha.2026.119020_bib179","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119020_bib180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2020.11.014","article-title":"The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology","volume":"144","author":"Wienke","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119020_bib181","article-title":"The significance of CD8+ tumor-infiltrating lymphocytes exhaustion heterogeneity and its underlying mechanism in diffuse large B-cell lymphoma","author":"Zhu","year":"2024","journal-title":"Int Immunopharmacol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib182","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib183","article-title":"Therapy resistance in neuroblastoma: Mechanisms and reversal strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2026.119020_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: Revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119020_bib185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance Mechanisms to Anti-PD Cancer Immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004399","article-title":"Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119020_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119020_bib188","article-title":"LR. Advances and challenges in therapeutic resistant biomarkers of neuroblastoma: A comprehensive review","volume":"1879","author":"Arjunan","year":"2024","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119020_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174113","article-title":"MYCN and Metabolic Reprogramming in Neuroblastoma","author":"Bansal","year":"2022","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib190","article-title":"Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression","author":"Jin","year":"2024","journal-title":"Thera [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib191","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2025.10026","article-title":"Polyamine metabolism in cancer: drivers of immune evasion, ferroptosis and therapy resistance","author":"Chenna","year":"2025","journal-title":"Expert Rev. Mol. Med [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib192","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119020_bib193","first-page":"1","article-title":"Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasis","volume":"25","author":"Ghorbani vanan","year":"2025","journal-title":"Clin. Exp. Med [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2026.119020_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021294","article-title":"Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers","volume":"24","author":"Spiliopoulou","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119020_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051162","article-title":"Immune-related mutational landscape and gene signatures: Prognostic value and therapeutic impact for head and neck cancer","volume":"13","author":"Feng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119020_bib196","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.omto.2020.12.012","article-title":"Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies","volume":"20","author":"Wang","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2026.119020_bib197","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10278","key":"10.1016\/j.biopha.2026.119020_bib198","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119020_bib199","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001335","article-title":"Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma","author":"Seier","year":"2021","journal-title":"J. Immunother. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib200","article-title":"Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses","author":"Larkin","year":"2024","journal-title":"J. Transl. Med [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib201","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-23-1594","article-title":"Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers","author":"Zheng","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib202","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00181","article-title":"Differential Impact of ALK Mutations in Neuroblastoma","author":"O\u2019Donohue","year":"2021","journal-title":"JCO Precis Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib203","article-title":"Emerging Roles of ALK in Immunity and Insights for Immunotherapy","author":"Wang","year":"2020","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib204","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13071517","article-title":"Analysis of pro-inflammatory and anti-inflammatory cytokine serum concentrations in pediatric patients with neuroblastoma: a preliminary study","author":"Moreno-Guerrero","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119020_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092096","article-title":"Immune monitoring during therapy reveals activitory and regulatory immune responses in high-risk neuroblastoma","author":"Szanto","year":"2021","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib206","article-title":"Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures","author":"Wei","year":"2025","journal-title":"J. Immunother. Cancer [Internet]. 2023 Jul. 11 [cited"},{"key":"10.1016\/j.biopha.2026.119020_bib207","article-title":"Dissecting neuroblastoma heterogeneity through single-cell multi-omics: insights into development, immunity, and therapeutic resistance","volume":"45","author":"He","year":"2025","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2026.119020_bib208","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41588-025-02158-6","article-title":"Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring","volume":"57","author":"Yu","year":"2025","journal-title":"Nat. Genet [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib209","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041613","article-title":"Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors","volume":"26","author":"Lucarini","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119020_bib210","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of Immunotherapy Combination Strategies in Cancer","author":"Yap","year":"2021","journal-title":"Cancer Discov. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib211","article-title":"Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma","author":"Moreno","year":"2025","journal-title":"Eur. J. Cancer [Internet]. 2020 Sep 1 [cited"},{"key":"10.1016\/j.biopha.2026.119020_bib212","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1838140","article-title":"Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma","author":"Shirinbak","year":"2021","journal-title":"Oncoimmunology [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2024.100161","article-title":"The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies","author":"Louault","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2026.119020_bib214","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041068","article-title":"Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy","volume":"14","author":"Schramm","year":"2025","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2026.119020_bib215","article-title":"Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma","author":"Seier","year":"2025","journal-title":"J. Immunother. Cancer [Internet]. 2021 May 20 [cited"},{"key":"10.1016\/j.biopha.2026.119020_bib216","article-title":"[Internet","author":"Lin","year":"2023","journal-title":"Height. Import. EZH2 Cancer Immunother."},{"key":"10.1016\/j.biopha.2026.119020_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217393","article-title":"Metabolic targeting of neuroblastoma, an update","author":"Jahangiri","year":"2025","journal-title":"Cancer Lett. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib218","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09564-0","article-title":"Reprogramming neuroblastoma by diet-enhanced polyamine depletion","volume":"646","author":"Cherkaoui","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119020_bib219","article-title":"Polyamine metabolism and anti-tumor immunity","author":"Wu","year":"2025","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib220","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7207","article-title":"DFMO inhibition of neuroblastoma tumorigenesis","author":"Gandra","year":"2024","journal-title":"Cancer Med [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib221","article-title":"Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score\u2013matched survival outcome comparisons","author":"Oesterheld","year":"2023","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-20896-z","article-title":"Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119020_bib223","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.13789","article-title":"The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma","author":"Azfar","year":"2025","journal-title":"Mol. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib224","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02478","article-title":"Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children\u2019s Oncology Group","author":"Desai","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib225","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-025-01155-3","article-title":"Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed\/Refractory High-Risk Neuroblastoma","author":"Wieczorek","year":"2025","journal-title":"Target Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib226","doi-asserted-by":"crossref","unstructured":"Yu A.L., Gilman A.L., Ozkaynak M.F., Naranjo A., Diccianni M.B., Gan J., et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clinical Cancer Research [Internet]. 2021 Apr 1 [cited 2025 Dec 25];27(8):2179\u201389. Available from: \/clincancerres\/article\/27\/8\/2179\/672055\/Long-Term-Follow-up-of-a-Phase-III-Study-of-ch14.","DOI":"10.1158\/1078-0432.CCR-20-3909"},{"key":"10.1016\/j.biopha.2026.119020_bib227","unstructured":"Study Details | NCT07027748 | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT07027748\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib228","unstructured":"Study Details | NCT05782959 | Phase 1 Study of BCD-245 in Subjects With Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05782959\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib229","unstructured":"Study Details | NCT05421897 | Rapid Administration Pilot for Infusing Dinutuximab | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT05421897\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib230","unstructured":"Study Details | NCT06528496 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06528496?cond=Neuroblastoma&rank=4\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib231","unstructured":"Study Details | NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory\/ Relapsed Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT06013618?term=Naxitamab&rank=10\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib232","unstructured":"Study Details | NCT04936529 | A Study of a Vaccine in Combination With \u03b2-glucan and GM-CSF in People With Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT04936529\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib233","unstructured":"Study Details | NCT06057948 | A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT06057948?cond=Neuroblastoma%20OR%20%22neural%20Crest%20tumor,%20malignant%22%20OR%20%22%20neuroblastoma%20\u3009(Schwannian%20Stroma-poor)%22%20OR%20%22%20neuroblastoma,%20malignant%22&aggFilters=status:not%20rec&viewType=Table&rank=6."},{"key":"10.1016\/j.biopha.2026.119020_bib234","unstructured":"Study Details | NCT04385277 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT04385277\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib235","unstructured":"Study Details | NCT05489887 | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05489887\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib236","unstructured":"Study Details | NCT06438614 | A Study Of Naxitamab, Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed \/Refractory, Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06438614\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib237","unstructured":"Study Details | NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04238819\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib238","unstructured":"Study Details | NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed\/Refractory Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT06948994\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib239","unstructured":"Study Details | NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT06071897\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib240","unstructured":"Study Details | NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | ClinicalTrials.gov [Internet]. [cited 2025 Nov 5]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06047535\u3009."},{"key":"10.1016\/j.biopha.2026.119020_bib241","article-title":"GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system","volume":"9","author":"Fern\u00e1ndez-Rilo","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119020_bib242","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34808","article-title":"A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR project","author":"Evans","year":"2024","journal-title":"Int J. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib243","doi-asserted-by":"crossref","unstructured":"Anderson J., Majzner R.G., Sondel P.M.. Immunotherapy of Neuroblastoma: Facts and Hopes. Clinical Cancer Research [Internet]. 2022 Aug 1 [cited 2025 Dec 25];28(15):3196\u2013206. Available from: \/clincancerres\/article\/28\/15\/3196\/707108\/Immunotherapy-of-Neuroblastoma-Facts-and.","DOI":"10.1158\/1078-0432.CCR-21-1356"},{"key":"10.1016\/j.biopha.2026.119020_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2024.100161","article-title":"The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies","author":"Louault","year":"2024","journal-title":"EJC Paediatr. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib245","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","author":"Locatelli","year":"2025","journal-title":"Nat. Med [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib246","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","author":"Mabe","year":"2022","journal-title":"Nat. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119020_bib247","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1249929","article-title":"Biology of GD2 ganglioside: implications for cancer immunotherapy","volume":"14","author":"Machy","year":"2023","journal-title":"Front Pharm."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.119939","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000}},{"DOI":"10.1016\/j.biopha.2026.119939","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:39:18Z","timestamp":1781879958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":247,"alternative-id":["S0753332226000521"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119020","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119020"}}